Sabrina A Assoumou1,2, Abriana Tasillo1, Jared A Leff3, Bruce R Schackman3, Mari-Lynn Drainoni2,4,5, C Robert Horsburgh1,6, M Anita Barry7, Craig Regis7, Arthur Y Kim8, Alison Marshall9,10,11, Sheel Saxena11, Peter C Smith1,12, Benjamin P Linas1,2,6. 1. Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Massachusetts. 2. Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Massachusetts. 3. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York. 4. Department of Health Law, Policy and Management, Boston University School of Public Health. 5. Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford. 6. Department of Epidemiology, Boston University School of Public Health. 7. Infectious Disease Bureau, Boston Public Health Commission. 8. Division of Infectious Diseases, Massachusetts General Hospital. 9. Boston College Connell School of Nursing. 10. STD/HIV Prevention Center of New England, Jamaica Plain. 11. South Boston Community Health Center. 12. Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine, Massachusetts.
Abstract
Background: High hepatitis C virus (HCV) rates have been reported in young people who inject drugs (PWID). We evaluated the clinical benefit and cost-effectiveness of testing among youth seen in communities with a high overall number of reported HCV cases. Methods: We developed a decision analytic model to project quality-adjusted life years (QALYs), costs (2016 US$), and incremental cost-effectiveness ratios (ICERs) of 9 strategies for 1-time testing among 15- to 30-year-olds seen at urban community health centers. Strategies differed in 3 ways: targeted vs routine testing, rapid finger stick vs standard venipuncture, and ordered by physician vs by counselor/tester using standing orders. We performed deterministic and probabilistic sensitivity analyses (PSA) to evaluate uncertainty. Results: Compared to targeted risk-based testing (current standard of care), routine testing increased the lifetime medical cost by $80 and discounted QALYs by 0.0013 per person. Across all strategies, rapid testing provided higher QALYs at a lower cost per QALY gained and was always preferred. Counselor-initiated routine rapid testing was associated with an ICER of $71000/QALY gained. Results were sensitive to offer and result receipt rates. Counselor-initiated routine rapid testing was cost-effective (ICER <$100000/QALY) unless the prevalence of PWID was <0.59%, HCV prevalence among PWID was <16%, reinfection rate was >26 cases per 100 person-years, or reflex confirmatory testing followed all reactive venipuncture diagnostics. In PSA, routine rapid testing was the optimal strategy in 90% of simulations. Conclusions: Routine rapid HCV testing among 15- to 30-year-olds may be cost-effective when the prevalence of PWID is >0.59%.
Background: High hepatitis C virus (HCV) rates have been reported in young people who inject drugs (PWID). We evaluated the clinical benefit and cost-effectiveness of testing among youth seen in communities with a high overall number of reported HCV cases. Methods: We developed a decision analytic model to project quality-adjusted life years (QALYs), costs (2016 US$), and incremental cost-effectiveness ratios (ICERs) of 9 strategies for 1-time testing among 15- to 30-year-olds seen at urban community health centers. Strategies differed in 3 ways: targeted vs routine testing, rapid finger stick vs standard venipuncture, and ordered by physician vs by counselor/tester using standing orders. We performed deterministic and probabilistic sensitivity analyses (PSA) to evaluate uncertainty. Results: Compared to targeted risk-based testing (current standard of care), routine testing increased the lifetime medical cost by $80 and discounted QALYs by 0.0013 per person. Across all strategies, rapid testing provided higher QALYs at a lower cost per QALY gained and was always preferred. Counselor-initiated routine rapid testing was associated with an ICER of $71000/QALY gained. Results were sensitive to offer and result receipt rates. Counselor-initiated routine rapid testing was cost-effective (ICER <$100000/QALY) unless the prevalence of PWID was <0.59%, HCV prevalence among PWID was <16%, reinfection rate was >26 cases per 100 person-years, or reflex confirmatory testing followed all reactive venipuncture diagnostics. In PSA, routine rapid testing was the optimal strategy in 90% of simulations. Conclusions: Routine rapid HCV testing among 15- to 30-year-olds may be cost-effective when the prevalence of PWID is >0.59%.
Authors: Sudip Chatterjee; Barbara Tempalski; Enrique R Pouget; Hannah L F Cooper; Charles M Cleland; Samuel R Friedman Journal: AIDS Behav Date: 2011-10
Authors: Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard Journal: J Infect Dis Date: 2015-04-15 Impact factor: 5.226
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas Journal: Addiction Date: 2015-01 Impact factor: 7.256
Authors: Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman Journal: PLoS One Date: 2014-05-19 Impact factor: 3.752
Authors: Barbara Tempalski; Enrique R Pouget; Charles M Cleland; Joanne E Brady; Hannah L F Cooper; H Irene Hall; Amy Lansky; Brooke S West; Samuel R Friedman Journal: PLoS One Date: 2013-06-05 Impact factor: 3.240
Authors: Sabrina A Assoumou; Shayla Nolen; Liesl Hagan; Jianing Wang; Golnaz Eftekhari Yazdi; William W Thompson; Kenneth H Mayer; Jon Puro; Lin Zhu; Joshua A Salomon; Benjamin P Linas Journal: Am J Med Date: 2020-06-27 Impact factor: 4.965
Authors: Joshua A Barocas; Abriana Tasillo; Golnaz Eftekhari Yazdi; Jianing Wang; Claudia Vellozzi; Susan Hariri; Cheryl Isenhour; Liisa Randall; John W Ward; Jonathan Mermin; Joshua A Salomon; Benjamin P Linas Journal: Clin Infect Dis Date: 2018-08-01 Impact factor: 20.999
Authors: Ellen Childs; Sabrina A Assoumou; Katie B Biello; Dea L Biancarelli; Mari-Lynn Drainoni; Alberto Edeza; Peter Salhaney; Matthew J Mimiaga; Angela R Bazzi Journal: Harm Reduct J Date: 2019-02-11